Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs ResMed Inc. — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.28, while ResMed Inc. trades at $195.32 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while KraneShares Hang Seng TECH Index ETF pays none. Which is the better fit depends on your goals.
| KTEC | RMD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $19.51 | $293.73 |
52-Week Low | $12.00 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC stock is trading at $13.28, up 2.23% today, showing positive momentum. The stock's technical picture indicates recent strength, though key financial ratios including P/E, P/S, and profitability metrics are currently unavailable for analysis. No recent earnings data or business developments are accessible to provide fundamental context.
Investment outlook remains unclear due to insufficient financial data. The primary opportunity lies in the stock's recent price appreciation, while risks include limited transparency on company fundamentals and the absence of analyst coverage or institutional positioning data to validate current valuation levels.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
